Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 19 | 2023 | 12183 | 1.510 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 8 | 2023 | 4865 | 0.930 |
Why?
|
Early Detection of Cancer | 5 | 2022 | 2865 | 0.820 |
Why?
|
Carcinoma, Small Cell | 1 | 2020 | 413 | 0.660 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2021 | 813 | 0.630 |
Why?
|
Small Cell Lung Carcinoma | 4 | 2021 | 356 | 0.580 |
Why?
|
Costs and Cost Analysis | 1 | 2017 | 1652 | 0.420 |
Why?
|
Nervous System Diseases | 1 | 2020 | 1630 | 0.380 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2019 | 3708 | 0.310 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2019 | 3876 | 0.300 |
Why?
|
Mutation | 4 | 2023 | 29262 | 0.270 |
Why?
|
Carbolines | 2 | 2020 | 249 | 0.220 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2022 | 11253 | 0.180 |
Why?
|
Teaching Rounds | 1 | 2022 | 223 | 0.180 |
Why?
|
Mass Screening | 4 | 2022 | 5182 | 0.170 |
Why?
|
Endogenous Retroviruses | 1 | 2018 | 103 | 0.160 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2022 | 3515 | 0.140 |
Why?
|
Carcinoma in Situ | 1 | 2021 | 821 | 0.140 |
Why?
|
Urethral Neoplasms | 1 | 2014 | 40 | 0.130 |
Why?
|
Interferons | 1 | 2018 | 667 | 0.130 |
Why?
|
Adenocarcinoma | 2 | 2022 | 6338 | 0.130 |
Why?
|
Amino Acid Substitution | 1 | 2017 | 1823 | 0.110 |
Why?
|
Neoplasm Staging | 6 | 2022 | 11126 | 0.110 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1782 | 0.110 |
Why?
|
Humans | 23 | 2023 | 708843 | 0.100 |
Why?
|
Medical Oncology | 2 | 2021 | 2098 | 0.100 |
Why?
|
Tomography, X-Ray Computed | 3 | 2022 | 20308 | 0.090 |
Why?
|
Gene Expression | 1 | 2021 | 8014 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2021 | 8877 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 9488 | 0.080 |
Why?
|
Immunity, Innate | 1 | 2018 | 2937 | 0.070 |
Why?
|
DNA | 1 | 2020 | 7172 | 0.070 |
Why?
|
Immunotherapy | 1 | 2021 | 4057 | 0.070 |
Why?
|
Alleles | 1 | 2017 | 7090 | 0.070 |
Why?
|
Retrospective Studies | 6 | 2022 | 71483 | 0.060 |
Why?
|
Neoplasms | 2 | 2022 | 20172 | 0.060 |
Why?
|
Lung | 1 | 2020 | 9706 | 0.050 |
Why?
|
Prognosis | 2 | 2022 | 28919 | 0.050 |
Why?
|
Technology | 1 | 2021 | 237 | 0.050 |
Why?
|
Aged | 6 | 2022 | 161488 | 0.040 |
Why?
|
Male | 8 | 2022 | 349524 | 0.040 |
Why?
|
RNA, Antisense | 1 | 2018 | 144 | 0.040 |
Why?
|
Female | 8 | 2022 | 375205 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2021 | 347 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39038 | 0.040 |
Why?
|
Carboplatin | 1 | 2021 | 797 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2018 | 8776 | 0.040 |
Why?
|
Middle Aged | 6 | 2022 | 213752 | 0.040 |
Why?
|
Adult | 4 | 2020 | 211041 | 0.040 |
Why?
|
Morbidity | 1 | 2022 | 1690 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2018 | 919 | 0.040 |
Why?
|
Survival Analysis | 2 | 2021 | 10507 | 0.040 |
Why?
|
Cisplatin | 1 | 2022 | 1651 | 0.040 |
Why?
|
United States | 2 | 2020 | 67165 | 0.040 |
Why?
|
Cranial Irradiation | 1 | 2018 | 435 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2021 | 882 | 0.030 |
Why?
|
Paclitaxel | 1 | 2021 | 1655 | 0.030 |
Why?
|
Doxorubicin | 1 | 2020 | 2235 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2022 | 2041 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2018 | 2927 | 0.030 |
Why?
|
Pneumonectomy | 1 | 2018 | 1066 | 0.030 |
Why?
|
Mice, Nude | 1 | 2018 | 3859 | 0.030 |
Why?
|
Dietary Proteins | 1 | 1995 | 967 | 0.020 |
Why?
|
Membrane Transport Proteins | 1 | 1995 | 1024 | 0.020 |
Why?
|
Cohort Studies | 2 | 2022 | 39292 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2020 | 7026 | 0.020 |
Why?
|
Biopsy | 1 | 2021 | 6766 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2021 | 11239 | 0.020 |
Why?
|
Treatment Outcome | 3 | 2020 | 61932 | 0.020 |
Why?
|
Quality Improvement | 1 | 2022 | 3733 | 0.020 |
Why?
|
Societies, Medical | 1 | 2018 | 3776 | 0.020 |
Why?
|
Survival Rate | 1 | 2021 | 13202 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 3693 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 5982 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 1995 | 3812 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2021 | 58184 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8638 | 0.010 |
Why?
|
Carrier Proteins | 1 | 1995 | 5141 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2018 | 16959 | 0.010 |
Why?
|
Kidney | 1 | 1995 | 6888 | 0.010 |
Why?
|
Risk Assessment | 1 | 2021 | 23284 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 1995 | 12447 | 0.010 |
Why?
|
Diuresis | 1 | 1995 | 121 | 0.010 |
Why?
|
Models, Structural | 1 | 1995 | 380 | 0.010 |
Why?
|
Kidney Medulla | 1 | 1995 | 191 | 0.010 |
Why?
|
Urea | 1 | 1995 | 441 | 0.010 |
Why?
|
Adolescent | 1 | 2020 | 84718 | 0.010 |
Why?
|
Protein Structure, Secondary | 1 | 1995 | 1232 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1995 | 2100 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 1995 | 1988 | 0.010 |
Why?
|
Xenopus laevis | 1 | 1995 | 1012 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1995 | 2926 | 0.010 |
Why?
|
Oocytes | 1 | 1995 | 1217 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 1995 | 4489 | 0.010 |
Why?
|
Rabbits | 1 | 1995 | 5163 | 0.010 |
Why?
|
Animals | 2 | 2018 | 170486 | 0.010 |
Why?
|
Cell Membrane | 1 | 1995 | 3892 | 0.000 |
Why?
|
Recombinant Proteins | 1 | 1995 | 6850 | 0.000 |
Why?
|
Rats, Sprague-Dawley | 1 | 1995 | 8593 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1995 | 14215 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1995 | 18748 | 0.000 |
Why?
|
Transcription, Genetic | 1 | 1995 | 7965 | 0.000 |
Why?
|
Rats | 1 | 1995 | 25094 | 0.000 |
Why?
|
Models, Biological | 1 | 1995 | 9907 | 0.000 |
Why?
|
Concepts
(104)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(30)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_